- Home
- DDI vs ADCT Comparison
DDI vs ADCT Comparison
Compare DDI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DDI | ADCT |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | South Korea | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.3M | 454.5M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DDI | ADCT |
|---|---|---|
| Price | $9.20 | $3.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $19.25 | $7.60 |
| AVG Volume (30 Days) | 55.3K | ★ 1.4M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.12 | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $346,122,000.00 | $75,209,000.00 |
| Revenue This Year | $16.48 | $10.36 |
| Revenue Next Year | $7.89 | $3.87 |
| P/E Ratio | $4.01 | ★ N/A |
| Revenue Growth | 1.07 | ★ 6.35 |
| 52 Week Low | $8.09 | $1.05 |
| 52 Week High | $13.49 | $4.80 |
Technical Indicators
Market Signals| Indicator | DDI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 33.47 |
| Support Level | $9.12 | $2.94 |
| Resistance Level | $9.30 | $4.62 |
| Average True Range (ATR) | 0.29 | 0.35 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 64.20 | 21.13 |
Price Performance
Historical ComparisonAbout DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).